Skip to main content
SupplementScience

Benefits of Omega-3 Fish Oil

This content is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement. Full disclaimer

Evidence-Based Benefits

  • Inflammation reduction — a 2019 meta-analysis (Li et al., 68 RCTs, n=4,601) found omega-3 supplementation significantly reduced CRP, IL-6, and TNF-alpha levels across diverse populations
  • Cardiovascular protection — the REDUCE-IT trial (Bhatt et al., 2019, n=8,179) demonstrated 4g/day icosapent ethyl (EPA) reduced major cardiovascular events by 25% in high-risk patients
  • Triglyceride reduction — multiple meta-analyses confirm 2-4g EPA+DHA daily lowers triglycerides by 15-25%, with FDA-approved prescription formulations for severe hypertriglyceridemia
  • Joint inflammation — a 2017 meta-analysis (Senftleber et al., 30 RCTs) found omega-3s modestly reduced joint pain in rheumatoid arthritis and osteoarthritis patients
  • Resolution of inflammation — EPA and DHA are converted to resolvins, protectins, and maresins that actively resolve inflammatory responses rather than just suppressing them

What the Research Says

Omega-3 fish oil is among the most extensively studied supplements worldwide. The landmark REDUCE-IT trial (Bhatt et al., 2019) demonstrated that high-dose EPA (4g icosapent ethyl) reduced cardiovascular events by 25% in statin-treated patients with elevated triglycerides. For inflammation, a comprehensive meta-analysis by Li et al. (2019, 68 RCTs) confirmed significant reductions in CRP, IL-6, and TNF-alpha. The VITAL trial (Manson et al., 2019, n=25,871) found modest cancer risk reduction with 1g/day but no cardiovascular benefit at that low dose, underscoring that 2g+ daily is needed for anti-inflammatory effects. Mechanistically, EPA and DHA produce specialized pro-resolving mediators (resolvins, protectins) that actively resolve inflammation.

Related Conditions

InflammationHeart DiseaseJoint Pain
Full Omega-3 Fish Oil Guide

References

  1. (). Almond consumption and cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials. Advances in Nutrition. DOI
  2. (). Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine. DOI
  3. (). Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochemical Society Transactions. DOI